Cargando…

A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers

BACKGROUND: Multiplatform molecular subtyping has been put into clinical practice as an alternative for The Cancer Genome Atlas (TCGA)-based classification for endometrial cancer (EC), which proved a tool for predicting prognosis and guiding treatment. The traditional methods for the molecular class...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang, Feng, Junnan, Zhao, Chengzhi, Meng, Lin, Shi, Shanshan, Liu, Kangdong, Ma, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469165/
https://www.ncbi.nlm.nih.gov/pubmed/36111057
http://dx.doi.org/10.21037/atm-22-3446
_version_ 1784788580482154496
author Li, Yang
Feng, Junnan
Zhao, Chengzhi
Meng, Lin
Shi, Shanshan
Liu, Kangdong
Ma, Jie
author_facet Li, Yang
Feng, Junnan
Zhao, Chengzhi
Meng, Lin
Shi, Shanshan
Liu, Kangdong
Ma, Jie
author_sort Li, Yang
collection PubMed
description BACKGROUND: Multiplatform molecular subtyping has been put into clinical practice as an alternative for The Cancer Genome Atlas (TCGA)-based classification for endometrial cancer (EC), which proved a tool for predicting prognosis and guiding treatment. The traditional methods for the molecular classification of EC only based on pathological indicators are not accurate. The present study aimed to classify EC on a molecular level and explored the possibility of a one-time solution to guide clinical treatment and prognosis determination by utilizing data from a next-generation sequencing (NGS) panel. The ultimate aim was to utilize multiplatform testing to overcome disadvantages of long detection periods and limitations in the information regarding genetic variation. METHODS: An NGS-panel was produced using FFPE samples isolated from 86 patients pathologically diagnosed with EC, and molecular subtyping was performed according to the recommended criteria. In addition, 45 matched samples from 86 patients were randomly selected for immunohistochemical (IHC) staining of P53, MLH1, MSH2, PMS2, and MSH6. Another 41 samples were not analyzed due to incomplete IHC staining results. SPSS (V26.0; IBM Corp., Armonk, NY, USA) was used for receiver operating characteristic (ROC) curve analysis. RESULTS: The molecular typing ratio of the 86 cases of endometrial carcinoma was calculated to be 16.28% for POLE type, 17.44% for MSI-H type, 47.67% for CN-L type, 12.79% for CN-H type, 5.81% for unclassified case. A comparison between IHC ProMisE-based subtyping and NGS-based subtyping of the 45 cases revealed that 3 cases were classified as MSI-H by IHC but as MSS by NGS. Among these cases, 1 case was deficient in MLH1 expression and PMS2 protein expression but had wild-type P53 protein, and the P53 sequencing data of this sample showed a missense mutation. Good overall consistency between the 2 determination methods was shown. Receiver operating characteristic (ROC) analysis showed that NGS had particularly high specificity and sensitivity for detecting the MSI and CN subtypes [area under the curve (AUC) =0.893>0.5, P=0.000029<0.01]. CONCLUSIONS: The present study suggested that NGS-based subtyping could serve as an effective approach for the molecular typing of EC. Both NGS and IHC bear their own unique advantages and challenges in clinical practice.
format Online
Article
Text
id pubmed-9469165
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-94691652022-09-14 A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers Li, Yang Feng, Junnan Zhao, Chengzhi Meng, Lin Shi, Shanshan Liu, Kangdong Ma, Jie Ann Transl Med Original Article BACKGROUND: Multiplatform molecular subtyping has been put into clinical practice as an alternative for The Cancer Genome Atlas (TCGA)-based classification for endometrial cancer (EC), which proved a tool for predicting prognosis and guiding treatment. The traditional methods for the molecular classification of EC only based on pathological indicators are not accurate. The present study aimed to classify EC on a molecular level and explored the possibility of a one-time solution to guide clinical treatment and prognosis determination by utilizing data from a next-generation sequencing (NGS) panel. The ultimate aim was to utilize multiplatform testing to overcome disadvantages of long detection periods and limitations in the information regarding genetic variation. METHODS: An NGS-panel was produced using FFPE samples isolated from 86 patients pathologically diagnosed with EC, and molecular subtyping was performed according to the recommended criteria. In addition, 45 matched samples from 86 patients were randomly selected for immunohistochemical (IHC) staining of P53, MLH1, MSH2, PMS2, and MSH6. Another 41 samples were not analyzed due to incomplete IHC staining results. SPSS (V26.0; IBM Corp., Armonk, NY, USA) was used for receiver operating characteristic (ROC) curve analysis. RESULTS: The molecular typing ratio of the 86 cases of endometrial carcinoma was calculated to be 16.28% for POLE type, 17.44% for MSI-H type, 47.67% for CN-L type, 12.79% for CN-H type, 5.81% for unclassified case. A comparison between IHC ProMisE-based subtyping and NGS-based subtyping of the 45 cases revealed that 3 cases were classified as MSI-H by IHC but as MSS by NGS. Among these cases, 1 case was deficient in MLH1 expression and PMS2 protein expression but had wild-type P53 protein, and the P53 sequencing data of this sample showed a missense mutation. Good overall consistency between the 2 determination methods was shown. Receiver operating characteristic (ROC) analysis showed that NGS had particularly high specificity and sensitivity for detecting the MSI and CN subtypes [area under the curve (AUC) =0.893>0.5, P=0.000029<0.01]. CONCLUSIONS: The present study suggested that NGS-based subtyping could serve as an effective approach for the molecular typing of EC. Both NGS and IHC bear their own unique advantages and challenges in clinical practice. AME Publishing Company 2022-08 /pmc/articles/PMC9469165/ /pubmed/36111057 http://dx.doi.org/10.21037/atm-22-3446 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Li, Yang
Feng, Junnan
Zhao, Chengzhi
Meng, Lin
Shi, Shanshan
Liu, Kangdong
Ma, Jie
A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers
title A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers
title_full A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers
title_fullStr A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers
title_full_unstemmed A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers
title_short A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers
title_sort new strategy in molecular typing: the accuracy of an ngs panel for the molecular classification of endometrial cancers
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469165/
https://www.ncbi.nlm.nih.gov/pubmed/36111057
http://dx.doi.org/10.21037/atm-22-3446
work_keys_str_mv AT liyang anewstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT fengjunnan anewstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT zhaochengzhi anewstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT menglin anewstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT shishanshan anewstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT liukangdong anewstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT majie anewstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT liyang newstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT fengjunnan newstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT zhaochengzhi newstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT menglin newstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT shishanshan newstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT liukangdong newstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers
AT majie newstrategyinmoleculartypingtheaccuracyofanngspanelforthemolecularclassificationofendometrialcancers